


CLAIMSWe claim:

5 1. A method for the treatment of disorders responsive to opening of the KCNQ potassium channels in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I



wherein

R^1 is selected from hydrogen, halogen, C_{1-8} alkyl, phenyl, phenylalkyl, C_{3-6} heterocyclic, C_{3-6} heterocyclicmethyl, -CN, -OR, -NRR, -NRNCOR or $-\text{CF}_3$;

15 R^2 is selected from halogen, C_{1-8} alkyl, C_{3-7} cycloalkyl, phenyl, phenylalkyl, C_{3-6} heterocyclic, C_{3-6} heterocyclicmethyl, -CN, -OR, -NRR, -NRNCOR or $-\text{S---R}$;

R^3 is selected from hydrogen, halogen or C_{1-8} alkyl;


R^4 is selected from hydrogen, $-\text{CH}_3$ or $-\text{CH}_2\text{C}_6\text{H}_5$;

20 R^5 is selected from hydrogen, C_{1-8} alkyl, C_{3-7} cycloalkyl, phenyl, phenylalkyl, C_{3-6} heterocyclic or C_{3-6} heterocyclicmethyl; wherein each occurrence of R is independently selected from the group consisting of C_{1-8} alkyl, C_{3-7} alkynyl, phenyl, phenylalkyl, C_{3-6} heterocyclic and C_{3-6} heterocyclicmethyl.

25

2. The method of claim 1 wherein the compound of Formula I is selected from a compound having the structure

100025524 100241402



wherein

R¹ is hydrogen;

R² is selected from the group consisting of NR⁶R⁷, SR⁸, OR⁹, phenyl, and

5 thienyl; in which said phenyl is optionally substituted with one or
two C₁₋₃alkoxy groups;

R³ is selected from the group consisting of C₁₋₆alkyl, trifluoromethyl,
C₃₋₇cycloalkyl, C₃₋₇cycloalkylmethyl, phenyl, amino,
di(C₁₋₃alkyl)amino and pyrrolidinyl; in which said phenyl is optionally
10 substituted with a halogen;

R⁴ is selected from the group consisting of phenylmethyl, furanylmethyl,
and C₃₋₇cycloalkylmethyl; in which the phenyl of said phenylmethyl
is optionally substituted with one substituent selected from the
group consisting of halogen, C₁₋₃alkyl, di(C₁₋₃alkyl)amino,
15 trifluoromethyl, trifluoromethoxy, and trifluoromethylthio; and in
which the furanyl of said furanylmethyl is optionally substituted with
a C₁₋₃alkyl group;

R⁵ is hydrogen;

R⁶ and R⁷ are each independently selected from the group consisting of

20 hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇alkynyl, phenyl, and
phenylmethyl; in which said C₁₋₆alkyl is optionally substituted with a
hydroxy group and in which said phenyl is optionally substituted
with one or two substituents selected from the group consisting of
halogen, trifluoromethoxy, and nitro; or R⁶ and R⁷ taken together
25 with the nitrogen to which they are attached form a heterocyclic
ring selected from the group consisting of pyrrolidinyl, morpholinyl,
piperidinyl, homopiperidinyl, methylpiperidinyl, and 1,2,3,4-
tetrahydridoisoquinolinyl;

40025524 024702

R^8 is selected from the group consisting of C_{1-6} alkyl, C_{3-7} cycloalkyl, phenyl, phenylmethyl, furanylmethyl, and thienyl; in which said phenyl is optionally substituted with one halogen or nitro group; and

5 wherein the phenyl of said phenylmethyl is optionally substituted with one halogen or C_{1-3} alkyl group; and

R^9 is selected from the group consisting of C_{3-7} alkynyl, phenyl, 1-(4-fluorophenyl)ethyl, and thienylmethyl; in which said phenyl is optionally substituted with a halogen or C_{1-3} alkoxy group.

10

3. The method of claim 1 wherein said disorder is migraine or migraine-like attack.

4. The method of claim 2 wherein said disorder is migraine or

15 migraine-like attack.

5. A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective amount of the compound of claim 1 in association 20 with a pharmaceutically acceptable carrier, adjuvant or diluent.

6. A pharmaceutical composition for the treatment of disorders

responsive to opening of KCNQ potassium channels comprising a

therapeutically effective amount of the compound of claim 2 in association

25 with a pharmaceutically acceptable carrier, adjuvant or diluent.